The price of Neoleukin Therapeutics Inc. (NASDAQ:NLTX) shares last traded on Wall Street fell -0.90% to $0.53.
Based on available information, 5 analysts follow Neoleukin Therapeutics Inc. (NASDAQ:NLTX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $0.90, we find $1.00. Given the previous closing price of $0.54, this indicates a potential upside of 85.19 percent. NLTX stock price is now -3.27% away from the 50-day moving average and -30.13% away from the 200-day moving average. The market capitalization of the company currently stands at $22.88M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Among analysts, 5 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $1.30 as their price target over the next twelve months.
On January 06, 2021, Stifel recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘Robert W. Baird’ rates the stock as ‘Outperform’.
In other news, Patel Priti, Chief Medical Officer sold 14,380 shares of the company’s stock on Feb 02. The stock was sold for $8,588 at an average price of $0.60. Upon completion of the transaction, the Chief Medical Officer now directly owns 31,082 shares in the company, valued at $16473.46. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 02, Principal Accounting Officer Smith Sean Michael sold 3,316 shares of the business’s stock. A total of $1,980 was realized by selling the stock at an average price of $0.60. This leaves the insider owning 15,960 shares of the company worth $8458.8. Insiders disposed of 24,889 shares of company stock worth roughly $13191.17 over the past 1 year. A total of 21.49% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NLTX stock. A new stake in Neoleukin Therapeutics Inc. shares was purchased by LYNX1 CAPITAL MANAGEMENT LP during the first quarter worth $1,214,000. JANE STREET GROUP, LLC invested $32,000 in shares of NLTX during the first quarter. In the first quarter, HIGHTOWER ADVISORS, LLC acquired a new stake in Neoleukin Therapeutics Inc. valued at approximately $26,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in NLTX for approximately $14,000. KESTRA ADVISORY SERVICES, LLC purchased a new stake in NLTX valued at around $7,000 in the second quarter. In total, there are 73 active investors with 45.00% ownership of the company’s stock.
A candlestick chart of Neoleukin Therapeutics Inc. (NASDAQ: NLTX) showed a price of $0.5200 on Wednesday morning. During the past 12 months, Neoleukin Therapeutics Inc. has had a low of $0.38 and a high of $2.56. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.60, and a quick ratio of 10.60. The fifty day moving average price for NLTX is $0.5481 and a two-hundred day moving average price translates $0.7588 for the stock.
The latest earnings results from Neoleukin Therapeutics Inc. (NASDAQ: NLTX) was released for Sep, 2022.
Neoleukin Therapeutics Inc.(NLTX) Company Profile
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company’s lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
